High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Vainio, Paula ^a   Mpindi, John Patrick ^b   Kohonen, Pekka ^a   Fey, Vidal ^a   Mirtti, Tuomas ^b,c,d   Alanen, Kalle A ^e   Perälä, Merja ^a   Kallioniemi, Olli ^a,b   Iljin, Kristiina ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MEMBRANE PROTEIN; SMALL INTERFERING RNA;

AIM1 GENE; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; ERGIC1 GENE; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MITOSIS; ONCOGENE; PROSTATE CANCER; RNA ANALYSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TMED3 GENE; TPX2 GENE; TRANSCRIPTOMICS;

BLOTTING, WESTERN; CELL CYCLE PROTEINS; CRYSTALLINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTOME; VESICULAR TRANSPORT PROTEINS;

EID: 84862975903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039801     Document Type: Article

References (64)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
3. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, et al. (2004) Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64: 8867-8875.
4. Heinlein CA, Chang C, (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308. Review.
5. Hååg P, Bektic J, Bartsch G, Klocker H, Eder IE, (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96: 251-258.
6. Isaacs JT, Isaacs WB, (2004) Androgen receptor outwits prostate cancer drugs. Nat Med 10: 26-27.
7. Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, et al. (1999) Regulation of androgen action. Vitam Horm 55: 309-352. Review.
8. Debes JD, Tindall DJ, (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490.
9. Feldman BJ, Feldman D, (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
10. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
11. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, et al. (2008) Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68: 73-80.
12. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, et al. (2006) TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66: 3396-3400.
13. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
14. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, et al. (2010) FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 70: 6735-6745.
15. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, et al. (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66: 10242-10246.
16. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, et al. (2010) ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One 5: e10547.
17. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, et al. (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27: 5348-5353.
18. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
19. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, et al. (2009) ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A 106: 12465-12470.
20. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, et al. (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69: 2912-2918.
21. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, et al. (2006) TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66: 10658-10663.
22. Gimba ERP, Barcinski MA, (2003) Molecular aspects of prostate cancer: implications for future directions. Int Braz J Urol 29: 401-411.
23. Golias C, Charalabopoulos A, Stagikas D, Giannakopoulos X, Pescho D, et al. (2007) Molecular profiling and genomic microarrays in prostate cancer. Exp Oncol 29: 82-84.
24. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, et al. (2010) RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res 12: R41.
25. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, et al. (2011) RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 108: 3336-3341.
26. Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT, (2009) In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet 41: 1133-1137.
27. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, et al. (2008) Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 9: R139.
28. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
29. Brideau C, Gunter B, Pikounis B Liaw A, (2003) Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 6: 634-647.
30. Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, et al. (2011) Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol 178: 525-536.
31. Hayashi N, Koller E, Fazli L, Gleave ME, (2008) Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate 68: 1283-1295.
32. Reagan-Shaw S, Ahmad N, (2005) Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 19: 611-613.
33. DeYoung MP, Tress M, Narayanan R, (2003) Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors. Proc Natl Acad Sci U S A 100: 4760-4765.
34. Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, et al. (2008) Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer 123: 1318-1326.
35. Hu G, Wei Y, Kang Y, (2009) The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res 15: 5615-5620. Review.
36. Li W, Liu X, Wang W, Sun H, Hu Y, et al. (2008) Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus. Prostate 68: 1354-1361.
37. Morin PJ, (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65: 9603-9606.
38. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, et al. (2011) Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 30: 3962-3976.
39. Sved P, Scott KF, McLeod D, King NJ, Singh J, et al. (2004) Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 64: 6934-6940.
40. Wang H, Zhang C, Rorick A, Wu D, Chiu M, et al. (2011) CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res 71: 4866-4876.
41. Zhang C, Wang L, Wu D, Chen H, Chen Z, et al. (2011) Definition of a FoxA1 Cistrome that is Crucial for G1-S Phase Cell- Cycle Transit in Castration-Resistant Prostate Cancer. Cancer Res Sep 7. [Epub ahead of print].
42. Ray ME, Wistow G, Su YA, Meltzer PS, Trent JM, (1997) AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc Natl Acad Sci U S A 94: 3229-3234.
43. Ray ME, Su YA, Meltzer PS, Trent JM, (1996) Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma. Oncogene 12: 2527-2533.
44. Iqbal J, Kucuk C, Deleeuw RJ, Srivastava G, Tam W, et al. (2009) Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 23: 1139-1151.
45. Karube K, Nakagawa M, Tsuzuki S, Takeuchi I, Honma K, et al. (2011) Identification of FOXO3 and PRDM1 as tumor suppressor gene candidates in NK cell neoplasms by genomic and functional analyses. Blood 118: 3195-3204.
46. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, et al. (2008) Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 17: 2786-2794.
47. Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, et al. (2011) A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer 128: 1393-1403.
48. Araki S, Nakayama Y, Hori A, Yoshimura K, (2010) Biomarkers for predicting the sensitivity of cancer cells to TRAIL-R1 agonistic monoclonal antibody. Cancer Lett 292: 269-279.
49. Breuza L, Halbeisen R, Jenö P, Otte S, Barlowe C, et al. (2004) Proteomics of endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membranes from brefeldin A-treated HepG2 cells identifies ERGIC-32, a new cycling protein that interacts with human Erv46. J Biol Chem 279: 47242-47253.
50. Anantharaman V, Aravind L, (2002) The GOLD domain, a novel protein module involved in Golgi function and secretion. Genome Biol 3: research0023.
51. Liu Y, Ye Y, (2011) Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell Res 21: 867-883.
52. McLaughlin M, Vandenbroeck K, (2011) Review The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery? Br J Pharmacol 162: 328-345.
53. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, et al. (2009) Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) 2: 702-711.
54. Li B, Qi XQ, Chen X, Huang X, Liu GY, et al. (2010) Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res 1352: 200-207.
55. Stuart JE, Lusis EA, Scheck AC, Coons SW, Lal A, et al. (2011) Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol 70: 1-12.
56. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, et al. (2010) Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One 5: e9983.
57. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, et al. (2010) Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 16: 2518-2528.
58. Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, et al. (2009) Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res 15: 6519-6528.
59. Anderson K, Yang J, Koretke K, Nurse K, Calamari A, et al. (2007) Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry 46: 10287-10295.
60. Chowdhury A, Chowdhury S, Tsai MY, (2011) A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk Lymphoma [Epub ahead of print].
61. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, et al. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637.
62. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, et al. (2011) Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 30: 3716-3726.
63. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, et al. (2009) High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 15: 6070-6078.
64. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M, et al. (2002) Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21: 8749-8758.